文献速递前列腺癌

mpMRI能否改善前列腺癌主动监测临床选择标准

Does mpMRI improve clinical criteria in selecting men with prostate cancer for active surveillance?
PubMed 文献 · Prostate Cancer Prostatic Dis · 2017-04-25

该回顾性研究评估了208例根治性前列腺切除术前行mpMRI的男性,比较Epstein、NCCN低危和扩展标准三种临床标准单独或联合mpMRI选择主动监测的效能。联合mpMRI后NCCN低危标准的特异性从75%升至99.5%(P<0.01),AUC从0.78升至0.90(P<0.01);扩展标准特异性从47%升至97%(P<0.01),但敏感性从74%降至26%(P<0.01)。

要点

  • 联合mpMRI使NCCN低危标准的特异性从75%提高至99.5%,AUC从0.78提高至0.90。
  • 联合mpMRI使扩展标准的特异性从47%提高至97%,但敏感性从74%降至26%。
  • 仅1例在病理上符合Epstein标准,临床标准和mpMRI均未识别出该例。

核心结论

  • 联合mpMRI显著改善了使用NCCN低危标准选择主动监测男性的效能。
  • 对于选择预后分级组2有限的男性,mpMRI以牺牲敏感性为代价显著提高了特异性。

研究设计与样本

  • 回顾性评估2011年至2014年间根治性前列腺切除术前接受mpMRI的208例男性。

主要发现

  • 使用NCCN低危标准时,临床标准敏感性80%、特异性75%、LR+ 3.3、LR- 0.3、AUC 0.78。
  • 联合临床-mpMRI标准敏感性80%、特异性99.5%(P<0.01)、LR+ 162、LR- 0.2、AUC 0.90(与临床标准相比P<0.01)。
  • 使用扩展标准时,临床标准敏感性74%、特异性47%、LR+ 1.4、LR- 0.6、AUC 0.60。
  • 联合临床-mpMRI标准敏感性26%(P<0.01)、特异性97%(P<0.01)、LR+ 8.3、LR- 0.8、AUC 0.62(P=0.85)。
  • 仅1例在病理上符合Epstein标准,临床标准和mpMRI均未识别出该例。

关键数值与推荐

  • NCCN低危标准联合mpMRI:敏感性80%、特异性99.5%(P<0.01)、LR+ 162、LR- 0.2、AUC 0.90(与临床标准相比P<0.01)。
  • 扩展标准(Gleason ⩽3+4、PSA ⩽15 ng/ml、临床分期 ⩽T2b)联合mpMRI:敏感性26%(P<0.01)、特异性97%(P<0.01)、LR+ 8.3、LR- 0.8、AUC 0.62(P=0.85)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Active surveillance (AS) has excellent short to medium term outcomes in well-selected prostate cancer patients. Traditional biopsy-based selection criteria have been criticized for inaccurate determination of cancer grade and extent. We evaluated the incremental benefit of multiparametric magnetic resonance imaging (mpMRI) in patient selection using various AS criteria. METHODS: We retrospectively evaluated men who received mpMRI before radical prostatectomy between 2011 and 2014. Patients were classified as suitable for AS using four criteria: (1) Epstein, (2) National Comprehensive Cancer Network (NCCN) low-risk or (3) extended criteria (Gleason ⩽3+4, PSA ⩽15 ng/ml, clinical stage ⩽T2b) using clinical parameters. The incremental value of mpMRI was evaluated against the referent standard of surgical pathology in determining suitability for AS using sensitivity, specificity, likelihood ratios (LRs) and area under receiver operating curves (AUCs). RESULTS: We evaluated 208 men. Only one man fulfilled Epstein criteria (1) at pathology, who was neither identified using clinical criteria nor mpMRI. Using (2), clinical criteria had a sensitivity of 80%, specificity 75%, LR+ 3.3, LR- 0.3, AUC 0.78, while combined clinical-mpMRI criteria achieved a sensitivity of 80%, specificity 99.5% (P<0.01), LR+ 162, LR- 0.2 and AUC 0.90 (P<0.01 compared to clinical). Using (3), clinical criteria had a sensitivity of 74%, specificity 47%, LR+ 1.4, LR- 0.6, AUC 0.60, while combined clinical-mpMRI criteria achieved a sensitivity of 26% (P<0.01), specificity 97% (P<0.01), LR+ 8.3, LR- 0.8 and AUC 0.62 (P=0.85). CONCLUSIONS: Addition of mpMRI significantly improved selection of men for AS using NCCN low-risk criteria. For selecting men with limited prognostic grade group 2, mpMRI significantly improved specificity at the expense of sensitivity.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Tay KJ, Gupta RT, Holtz J, et al. Does mpMRI improve clinical criteria in selecting men with prostate cancer for active surveillance? Prostate Cancer Prostatic Dis. 2017. PMID: 28440322. doi:10.1038/pcan.2017.20

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。